... with spironolactone (MR antagonist, 50 mg/kg/day) or vehicle for 6 weeks. Spironolactone treatment did not affect blood pressure, fasting glucose levels or weight gain, but increased serum potassium and total cholesterol in both, diabetic and control mice. In addition, spironolactone significantly reduced serum...

... 1% NaCl in the drinking water in the absence and presence of BMS 182874 or of the aldosterone receptor blocker, spironolactone. Renal sections were used to assess inflammatory cell infiltration, which was identified immunocytochemically using monoclonal antibodies against macrophages (ED1...

... in subgroups of CHF patients with a large left ventricular end-systolic diameter (>55mm) or a low left ventricular ejection fraction (< 30%). CYP11B2 mRNA expression and CVF were lower in a CHF subgroup treated with a combination of spironolactone and angiotensin-converting enzyme inhibitors (ACEIs) than...

..., with concentrations in the luteal phase being significantly higher than those in the follicular phase. 6. The rise in urinary kallikrein excretion in the luteal phase could be abolished by oral administration of the aldosterone antagonist spironolactone. 7. Urinary kallikrein excretion in post-menopausal females...

...R. C. Gaillard; A. M. Riondel; P. Chabert; M. B. Vallotton 1. The action of spironolactone, a well-known antagonist of mineralocorticoids, on aldosterone regulation was investigated in normal young men to see whether it also acted as an inhibitor of biosynthesis in the adrenal gland. 2. The action...

... by albumin infusions. 3. Only the combined use of spironolactone and frusemide induced a natriuresis during indomethacin treatment. Spironolactone alone was ineffective. 4. It is suggested that inhibition of prostaglandin synthesis by indomethacin, in the presence of a stimulated renin-angiotensin system...

...U. Abshagen; S. Spörl; M. Schöneshöfer; M. L'Age; H. Rennekamp; W. Oelkers 1. Mild secondary hyperaldosteronism was induced in ten healthy young males by a low sodium diet for 14 days. After 7 days on the diet, five subjects each were treated with spironolactone (group S) or triamterene (group T...

... hypertensive with d-aldosterone and sodium chloride (10 g/l) drinking solution, (b) rats treated in the same manner but with the addition of spironolactone, and (c) control rats. 3. Hypertension developed in aldosterone-treated rats within 3–6 weeks and was associated with decreased plasma and renal renin...

... and decreased by spironolactone. 4. The results raised the possibility that kallikrein could be an aldosterone-induced protein. © 1976 The Biochemical Society and the Medical Research Society 1976 aldosterone hypertension kallikrein kidney sodium spironolactone Clinical Science and Molecular...

... with β-adrenergic blocking drugs. © 1994 The Biochemical Society and the Medical Research Society 1994 hypertension thiazides diazoxide spironolactone β-blockers prazosin Clinical Science and Molecular Medicine (1973) 45,75s-87s. A N E W LOOK A T T H E T R E A T M E N T O F SEVERE H Y P E...

...D. Kremer; D. G. Beevers; J. J. Brown; D. L. Davies; J. B. Ferriss; R. Fraser; A. F. Lever; J. I. S. Robertson 1. Prolonged treatment with spironolactone in low-renin hyperaldosteronism invariably corrects plasma electrolyte abnormalities and usually lowers blood pressure. 2. Total exchangeable...

...F. Mantero; D. Armanini; S. Urbani 1. The hypotensive effect of spironolactone has been studied in twenty-four patients with various forms of hypertension. 2. In essential hypertension a greater fall of blood pressure was achieved in patients with renin activity hyporesponsive to postural change...

... with deoxycorticosterone (20 mg/day; seven subjects), or spironolactone (200 mg/day; eight subjects), for 1 day before the day of study. 2. Treatment with deoxycorticosterone significantly ( P < 0·01) decreased sodium excretion (from a mean value of 391 to 192 μEq/min) and urine flow rate (from 14·3 to 12·4 ml min −1...